SCHEMBL2705497

SCHEMBL2705497

COc1ccc2c(c1)-c1nn(-c3ccccc3)cc1CN2S(=O)(=O)c1ccc(C)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 2/20 0.46
▸ CA1 P00915 2/20 0.46
▸ CA2 P00918 2/20 0.46
▸ CA9 Q16790 2/20 0.46
▸ MAPT P10636 2/20 0.43
▸ AURKA O14965 1/20 0.43
▸ TP53 P04637 1/20 0.43
▸ KMT2A Q03164 4/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ KCNN4 O15554 1/20 0.42
▸ KCNA3 P22001 1/20 0.42
▸ RYR2 Q92736 1/20 0.42
▸ LMNA P02545 3/20 0.42
▸ ALDH1A1 P00352 3/20 0.42
▸ KDM4E B2RXH2 1/20 0.42
▸ HPGD P15428 1/20 0.42
▸ L3MBTL1 Q9Y468 2/20 0.41
▸ ATM Q13315 1/20 0.41
▸ CDK2 P24941 3/20 0.40
▸ CCNE1 P24864 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2704449 0.93 ALDH1A1 (0.48) CA12CA1CA2CA9MAPT
SCHEMBL2704466 0.86 KCNN4 (0.54) CA12CA1CA2CA9MAPT
SCHEMBL2703634 0.78 KMT2A (0.47) MAPTTP53KMT2ASMN1; SMN2KCNN4
SCHEMBL8465682 0.73 MAOB (0.51) MAPTTP53KMT2ASMN1; SMN2KCNN4
SCHEMBL29101139 0.71 HSD11B1 (0.46) MAPTKMT2ASMN1; SMN2KCNN4KCNA3
SCHEMBL2705166 0.70 KDM4E (0.52) MAPTKMT2ASMN1; SMN2KCNN4KCNA3
SCHEMBL8466244 0.69 KMT2A (0.53) MAPTTP53KMT2ASMN1; SMN2KCNN4
SCHEMBL8465404 0.67 HTR6 (0.51) MAPTKMT2ASMN1; SMN2KCNN4KCNA3
SCHEMBL4928110 0.66 NPC1 (0.45) CA12CA9MAPTAURKAKMT2A
SCHEMBL2703631 0.66 KCNN4 (0.57) MAPTKMT2AKCNN4KCNA3LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2450358-A1 Fused, tricyclic sulfonamide inhibitors of gamma secretase Elan Pharmaceuticals Inc. (US) 2012-05-09 — — EP claimed
EP-2038280-A2 FUSED, TRICYCLIC SULFONAMIDE INHIBITORS OF GAMMA SECRETASE Elan Pharmaceuticals Inc. (US) 2009-03-25 — — EP claimed
US-20080021056-A1 Fused, Tricyclic Sulfonamide Inhibitors of Gamma Secretase ELAN PHARMACEUTICALS, INC. 2008-01-24 — — US claimed
WO-2007143523-A2 FUSED, TRICYCLIC SULFONAMIDE INHIBITORS OF GAMMA SECRETASE ELAN PHARMACEUTICALS, INC. (US) 2007-12-13 — — WO claimed
EP-2450358-A1 Fused, tricyclic sulfonamide inhibitors of gamma secretase Elan Pharmaceuticals Inc. (US) 2012-05-09 — — EP disclosed
EP-2038280-A2 FUSED, TRICYCLIC SULFONAMIDE INHIBITORS OF GAMMA SECRETASE Elan Pharmaceuticals Inc. (US) 2009-03-25 — — EP disclosed
US-20080021056-A1 Fused, Tricyclic Sulfonamide Inhibitors of Gamma Secretase ELAN PHARMACEUTICALS, INC. 2008-01-24 — — US disclosed
WO-2007143523-A2 FUSED, TRICYCLIC SULFONAMIDE INHIBITORS OF GAMMA SECRETASE ELAN PHARMACEUTICALS, INC. (US) 2007-12-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080021056-A1 Fused, Tricyclic Sulfonamide Inhibitors of Gamma Secretase BACE1, BACE2, PSEN1 CA12 1746/4885CA1 47/4885CA2 935/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback